Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 6/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499333 | 0.92 | BCL2 (0.50) | BCL2MCL1PLA2G2AALOX5AP | |
| SCHEMBL6488244 | 0.91 | LMNA (0.40) | BCL2MCL1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL6501220 | 0.89 | BCL2 (0.40) | BCL2MCL1MAPTPLA2G2ADCTPP1 | |
| SCHEMBL6489176 | 0.89 | BCL2 (0.38) | BCL2MCL1MEN1CYP3A4CYP2C9 | |
| SCHEMBL6498787 | 0.89 | BCL2 (0.40) | BCL2MCL1MAPTPLA2G2ADCTPP1 | |
| SCHEMBL6496885 | 0.88 | BCL2 (0.40) | BCL2MCL1MAPTDCTPP1TP53 | |
| SCHEMBL6490840 | 0.87 | BCL2 (0.46) | BCL2MCL1MAPTSMN1; SMN2PLA2G2A | |
| SCHEMBL6501511 | 0.87 | BCL2 (0.38) | BCL2MCL1MAPTDCTPP1TP53 | |
| SCHEMBL6490845 | 0.87 | OPRL1 (0.38) | BCL2MCL1MAPTSMN1; SMN2DCTPP1 | |
| SCHEMBL6492076 | 0.86 | BCL2 (0.40) | BCL2MCL1KMT2AMAPTPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | BCL2 774/4885MCL1 806/4885MEN1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.